7月31日，沪深两融数据显示，天臣医疗获融资买入额0.10亿元，居两市第1321位，当日融资偿还额0.09 亿元，净买入111.52万元。 最近三个交易日，29日-31日，天臣医疗分别获融资买入0.09亿元、0.16亿元、0.10亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

来源：金融界 天臣国际医疗科技股份有限公司的主营业务是专注于高端外科手术吻合器研发创新和生产销售。公司的 主要产品是腔镜吻合器类、管型吻合器类、线型切割吻合器类、荷包吻合器类、线型缝合吻合器类。公 司曾获得"苏州市级智能车间——微创外科吻合器智能制造车间"称号。 最新一期业绩显示，2025年一季报，公司实现营业收入6584.61万元，同比9.34%；净利润1318.67万 元，同比16.16%，销售毛利率58.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13天臣医疗58.0360.085.4531.18亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿1九安医疗11.0711.200.87186.87亿2英科医疗 14.0715.171.25222.33亿3新华医疗15.9114.751.30101.98亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2116.261.86153.29亿6奥美医疗16.3215.991.6858.96亿7康德莱17.1917.201.4237.04亿8九强生物 17.5016.272 ...

Group 1 - The core viewpoint of the article highlights the performance and valuation of Tianchen Medical, noting its stock price increase and current market metrics [1] - As of July 28, Tianchen Medical's closing price was 38.29 yuan, with a PE ratio of 57.84, marking a new low in 1133 days, and a total market capitalization of 3.107 billion yuan [1] - The average PE ratio in the medical device industry is 55.28, with a median of 38.06, placing Tianchen Medical at the 88th position in the industry ranking [1] Group 2 - As of March 31, 2025, Tianchen Medical had 4,443 shareholders, an increase of 68 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, innovation, production, and sales of high-end surgical staplers, with key products including various types of staplers and suturing devices [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 65.8461 million yuan, a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, up 16.16%, with a gross margin of 58.46% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tianchen Medical, which closed at 34.93 yuan with a PE ratio of 52.76 times, and a total market capitalization of 2.835 billion yuan [1] - The average PE ratio for the medical device industry is 54.56 times, with a median of 37.54 times, positioning Tianchen Medical at the 87th rank within the industry [1][2] - As of March 31, 2025, Tianchen Medical has 4,443 shareholders, an increase of 68 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tianchen Medical specializes in the research, innovation, production, and sales of high-end surgical staplers, with key products including endoscopic staplers, tubular staplers, linear cutting staplers, pouch staplers, and linear suturing staplers [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 65.8461 million yuan, representing a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, reflecting a year-on-year growth of 16.16%, with a gross profit margin of 58.46% [1]

Company Overview - Tianchen Medical closed at 32.75 yuan, up 2.99%, with a rolling PE ratio of 49.47, marking a new low in 1103 days, and a total market value of 2.658 billion yuan [1] - The company specializes in the research, innovation, production, and sales of high-end surgical anastomosis devices, including various types of endoscopic and linear cutting anastomosis devices [1] - As of the first quarter of 2025, seven institutions held shares in Tianchen Medical, with a total holding of 4.481 million shares valued at 0.85 million yuan [1] Financial Performance - For the first quarter of 2025, Tianchen Medical reported revenue of 65.8461 million yuan, a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, up 16.16%, with a gross profit margin of 58.46% [1] Industry Comparison - The average PE ratio for the medical device industry is 52.06, with a median of 37.22, placing Tianchen Medical at the 87th position within the industry [1] - The industry average PE ratio is 52.06, while the median is 37.22, indicating that Tianchen Medical's PE ratio is below the industry average but above the median [2]

Group 1 - The National Health Commission of China has issued notifications prohibiting the use of "ileal-jejunal anastomosis" for the treatment of type 2 diabetes and "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's disease treatment [2][3] - The cervical deep lymphatic vessel/lymph node-venous anastomosis is primarily used for treating stubborn lymphedema, but its application for Alzheimer's disease lacks clear indications and contraindications, as well as high-quality evidence supporting its safety and efficacy [2] - The ileal-jejunal anastomosis, used for restoring intestinal continuity, has been deemed to lack foundational theoretical support and high-quality evidence for its safety and efficacy in treating type 2 diabetes [3] Group 2 - The domestic anastomosis device market may be impacted by these prohibitions, with the top 10 manufacturers in China including Johnson & Johnson, Covidien, Frankmann, Yisi Medical, Tianchen Medical, Palt Medical, David Medical, Rich Surgical, Yintukang Medical, and Brolansense [3] - Relevant listed companies in this sector include Dongxing Medical and Tianchen Medical, which may face challenges due to the new regulations [3]

Core Viewpoint - Tianchen Medical (688013) has shown a positive stock performance with a closing price of 30.74 yuan, up 2.5% as of July 7, 2025, indicating a potential upward trend in investor sentiment [1] Financial Performance - The company reported a main revenue of 65.84 million yuan for Q1 2025, representing a year-on-year increase of 9.34% - The net profit attributable to shareholders was 13.19 million yuan, up 16.16% year-on-year - The net profit after deducting non-recurring gains and losses was 11.07 million yuan, with a slight increase of 0.5% year-on-year - The company's debt ratio stands at 13.25%, with investment income of 1.32 million yuan and financial expenses of -2.77 million yuan - The gross profit margin is reported at 58.46% [4] Market Position - Tianchen Medical's total market capitalization is 2.495 billion yuan, significantly lower than the industry average of 10.66 billion yuan, ranking 110 out of 122 in the medical device industry - The company's net assets are 572 million yuan, compared to the industry average of 3.919 billion yuan, ranking 114 out of 122 - The net profit of 13.19 million yuan ranks 77 out of 122 in the industry, while the price-to-earnings ratio (P/E) is 47.3, lower than the industry average of 57.66, ranking 58 out of 122 - The price-to-book ratio (P/B) is 4.69, higher than the industry average of 3.47, ranking 97 out of 122 - The company's net profit margin is 20.03%, significantly higher than the industry average of 10.86%, ranking 35 out of 122 - Return on equity (ROE) is reported at 2.38%, compared to the industry average of 1.01%, ranking 33 out of 122 [4] Capital Flow - On July 7, 2025, the net inflow of main funds was 104,200 yuan, accounting for 0.17% of the total transaction amount, while retail investors saw a net inflow of 1.68 million yuan, representing 2.76% of the total transaction amount - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from speculative funds [1][2]

截至2025年7月4日收盘，天臣医疗（688013）报收于29.99元，较上周的27.31元上涨9.81%。本周，天 臣医疗7月4日盘中最高价报31.96元，股价触及近一年最高点。6月30日盘中最低价报27.47元。天臣医疗 当前最新总市值24.34亿元，在医疗器械板块市值排名115/126，在两市A股市值排名4712/5149。 公司于2025年7月3日完成2023年限制性股票激励计划第二个归属期的股份登记工作。本次归属股票数量 为556,000股，来源于公司从二级市场回购的A股普通股股票，归属人数为89人。公司实际收到89名激励 对象缴纳的资本总额共计人民币5,977,000.00元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 天臣国际医疗科技股份有限公司于2023年12月27日开始实施股份回购计划，回购资金总额逐步调整为不 低于4600万元，不超过8000万元，回购期限延长至2025年12月26日。截至2025年6月30日，公司已累计 回购股份2505324股，占公司总股本的3.09%，支付的资金总额约为4249.89万 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-046 天臣国际医疗科技股份有限公司 关于 2022 年限制性股票激励计划首次及预留授予部分 第三个归属期归属结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次归属股票数量：189,006 股，其中首次授予部分 155,406 股，预留授 予部分 33,600 股 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司相关业务规定，天臣国际医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日收到中国证券登记结算有限责任公司出具的《过户登记确认书》， 公司完成了 2022 年限制性股票激励计划（以下简称"本次激励计划"）首次及预 留授予部分第三个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2022 年 5 月 5 日，公司召开第一届董事会第二十二次会议，会议审议通 过了《关于<公司 2022 年限制性股票激励计划（草案）>及其摘要的议案》《关 ...

第二个归属期归属结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 天臣国际医疗科技股份有限公司 关于 2023 年限制性股票激励计划 本次归属股票数量：556,000 股 证券代码：688013 证券简称：天臣医疗 公告编号：2025-045 1、2023 年 4 月 11 日，公司召开第二届董事会第三次会议，会议审议通过 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请 公司股东大会授权董事会办理股权激励相关事宜的议案》等议案。公司独立董事 就本次激励计划相关议案发表了同意的独立意见。 同日，公司召开第二届监事会第二次会议，审议通过了《关于公司<2023 年 限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股 票激励计划实施考核管理办法>的议案》以及《关于核实公司<2023 年限制性股 票激励计划激励对象名单>的议案》，公司监事会对本次激励计划的相关事项进 行核实并出 ...